Cali Biosciences
Simon Ho is an experienced financial professional currently serving as Group CFO at Cali Biosciences since September 2022. Prior to this role, Simon held the position of Chief Financial Officer and Company Secretary at Glory Sun Financial Group Limited from December 2018 to September 2022, where responsibilities included overseeing finance, taxation, corporate governance, and company secretary functions for a listed group with significant assets and turnover. Simon's experience also encompasses serving as Chief Financial Officer & Company Secretary at China Energy Development Holdings Limited, focusing on oil and gas exploration, and various managerial and audit roles at BDO Limited and Grant Thornton. Simon is a graduate of The Hong Kong Polytechnic University.
This person is not in any teams
This person is not in any offices
Cali Biosciences
Cali Biosciences is an international biopharmaceutical company dedicated to the research and development of innovative drugs. We have an international team of scientific research and management talents and is developing new drugs based on several patented technology platforms. We focus on the R&D of perioperative drugs. The product pipeline includes new drugs in the fields of anesthesia, analgesia, anti-inflammatory and anti-infection. In the future, we will also promote the commercialization of products to fully respond to the unmet market demand. The company focuses on the research and development of innovative drugs, with laboratories and offices in Shenzhen, China, and San Diego, USA, and a clinical development center in Shanghai, China. The company's main business is the R&D and production of innovative drugs, registration and application, as well as Sino-US market research, strategic operations and commercialization. The current product pipeline is consists of several modified new drugs based on the 505(b)(2) regulatory pathways. During the R&D process and upon completing the clinical trials, we seek approval from China, US and EU regulatory agencies and aiming at bringing innovative drugs in global markets. We are building a perioperative medication (anaesthesia, analgesia, anti-inflammatory, anti-infection) pipeline to meet the global unmet needs. At present, we have multiple clinical and pre-clinical stage drug candidates, the target market of the product pipeline is huge, and the clinical needs are clear. All the product pipeline is complex injection preparations with high technology patent threshold. Our goal is to serve patients and medical staff around the world, and our mission is to improve human survival and the quality of life.